Literature DB >> 29656006

Par-4-dependent p53 up-regulation plays a critical role in thymoquinone-induced cellular senescence in human malignant glioma cells.

Karthikeyan Subburayan1, Faisal Thayyullathil2, Siraj Pallichankandy3, Anees Rahman4, Sehamuddin Galadari5.   

Abstract

Thymoquinone (TQ), the predominant bioactive constituent present in black cumin (Nigella sativa), exerts tumor suppressive activity against a wide variety of cancer cells. Cellular senescence, characterized by stable and long term loss of proliferative capacity, acts as a potent tumor suppressive mechanism. Here, we provide evidence for the first time that TQ suppresses growth of glioma cells by potentially inducing the expression of prostate apoptosis response-4 (Par-4) tumor suppressor protein. In turn, TQ-induced Par-4 expression triggers cellular senescence, as evidenced by increasing cellular size, β-galactosidase staining, G1 phase arrest, and increased expression of senescence markers such as p53, p21, Rb, and decreased expression of lamin B1, cyclin E and cyclin depended kinase-2 (CDK-2). Further, overexpression of Par-4 significantly increases the expression of p53 and its downstream target p21, and increases β-galactosidase positive cells, while siRNA/shRNA mediated-knockdown of Par-4 reverses the TQ-induced effects. Altogether, we describe a novel mechanism of cross talk between Par-4 and p53, that plays a critical role in TQ-induced senescence in human malignant glioma cells.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Par-4; Senescence; Thymoquinone; p53; β-galactosidase

Mesh:

Substances:

Year:  2018        PMID: 29656006     DOI: 10.1016/j.canlet.2018.04.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

Review 1.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

2.  Inhibition of EMMPRIN by microRNA-124 suppresses the growth, invasion and tumorigenicity of gliomas.

Authors:  Yanbin Song; Lei Bai; Feiping Yan; Chen Chen
Journal:  Exp Ther Med       Date:  2021-07-01       Impact factor: 2.447

3.  Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency.

Authors:  Yu-Shui Ma; Xiao-Feng Wang; Yun-Jie Zhang; Pei Luo; Hui-Deng Long; Liu Li; Hui-Qiong Yang; Ru-Ting Xie; Cheng-You Jia; Gai-Xia Lu; Zheng-Yan Chang; Jia-Jia Zhang; Shao-Bo Xue; Zhong-Wei Lv; Fei Yu; Qing Xia; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2020-01-11       Impact factor: 7.200

4.  CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway.

Authors:  Zhenfu Jiang; Tongtong Gong; Hong Wei
Journal:  FEBS Open Bio       Date:  2020-01-21       Impact factor: 2.792

Review 5.  Nutritional Value and Preventive Role of Nigella sativa L. and Its Main Component Thymoquinone in Cancer: An Evidenced-Based Review of Preclinical and Clinical Studies.

Authors:  Johura Ansary; Francesca Giampieri; Tamara Y Forbes-Hernandez; Lucia Regolo; Denise Quinzi; Santos Gracia Villar; Eduardo Garcia Villena; Kilian Tutusaus Pifarre; José M Alvarez-Suarez; Maurizio Battino; Danila Cianciosi
Journal:  Molecules       Date:  2021-04-07       Impact factor: 4.411

Review 6.  Prostate apoptosis response-4 and tumor suppression: it's not just about apoptosis anymore.

Authors:  Anees Rahman Cheratta; Faisal Thayyullathil; Siraj Pallichankandy; Karthikeyan Subburayan; Ameer Alakkal; Sehamuddin Galadari
Journal:  Cell Death Dis       Date:  2021-01-07       Impact factor: 8.469

Review 7.  p53 Modulation of Autophagy Signaling in Cancer Therapies: Perspectives Mechanism and Therapeutic Targets.

Authors:  Md Ataur Rahman; Moon Nyeo Park; Md Hasanur Rahman; Md Mamunur Rashid; Rokibul Islam; Md Jamal Uddin; Md Abdul Hannan; Bonglee Kim
Journal:  Front Cell Dev Biol       Date:  2022-01-26

Review 8.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.